Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich repeat-containing protein 3B (LRRC3B)
- Target
- LRRC3B
- Molecular classification
- Other (Leucine-rich repeat protein), Integral membrane protein
01
Overview
Leucine-rich repeat-containing protein 3B (LRRC3B) is a membrane-associated protein characterized by leucine-rich repeat domains and is encoded by the LRRC3B gene, commonly located at chromosome 3p24.1. It acts primarily as a tumor suppressor and is frequently silenced by promoter hypermethylation in many epithelial cancers, including gastric, lung, renal, breast, ovarian, prostate, and colorectal cancers. Reduced LRRC3B expression is associated with poor prognoses and advanced tumor stage. LRRC3B regulates multiple cellular processes, including cell proliferation, cell cycle, apoptosis, cell adhesion, signal transduction, and plays a role in immune surveillance by influencing immune cell infiltration in the tumor microenvironment. DNA methylation of the LRRC3B promoter serves as a promising biomarker for cancer risk assessment, early detection, prognosis, and response prediction to cancer immunotherapy. No approved drugs are known to directly target LRRC3B; its clinical significance is mainly as a tumor suppressor and prognostic biomarker.
- Other names
- LRP15leucine-rich repeat protein 15UNQ195/PRO221leucine rich repeat containing 3BLRRC3Bleucine-rich repeat-containing protein 3B
02
Biological functions
Tumor suppression (inhibition of proliferation, colony formation, and invasion)Regulation of cell proliferationRegulation of cell cycle progressionModulation of immune response / immune surveillanceApoptosisCell adhesionSignal transductionRegulation of gene expression
03
Disease associations
Cancer (tumor suppressor, especially in gastric, renal, colorectal, lung, breast, ovarian, and prostate cancer)Immune regulation (possible role in tumor escape from immune surveillance)
04
Safety considerations
No major therapeutic targeting safety concerns described; as a tumor suppressor, loss or reduced function is the clinical problem
05
Biomarkers
DNA methylation status of the LRRC3B promoter for cancer diagnosis, prognosis, and prediction of response to immunotherapy (e.g., anti-PD-1/PD-L1 therapy)Expression level (prognostic in multiple cancer types, including breast, lung, kidney, bladder, and others)
Beyond the preview
Go deeper on Leucine-rich repeat-containing protein 3B (LRRC3B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leucine-rich repeat-containing protein 3B (LRRC3B).